Abstract
Herein, we assessed the expression of transglutaminase-2 (TG2) during in vitro neural differentiation of human Mesenchymal Stem Cells (hMSCs) induced by some Growth Factors (GFs). The amount and distribution of mRNAs for some transglutaminase (TGs) isoforms (TG1, TG2, TG3, TG5) were also evaluated. In addition, we tested some neural lineage markers (Glial Acid Fibrillary Protein, GFAP; Neurofilament Protein, NF; Nestin; β-Tubulin III). A progressive increase of all neural markers during GFs neural differentiation of hMSCs was found. A significant overexpression of TG1 and TG2 mRNA was observed in undifferentiated hMSCs. GFs-treatment induced a progressive decrease of TG1 mRNA during hMSCs differentiation. A significant down-regulation of TG2 mRNA in 2 days in vitro (DIV) GFs-treated cells was observed. TG2 mRNA progressively increased during GFs hMSCs differentiation, reaching after 6 DIV of GFs-treatment of similar values to those observed in undifferentiated cells. TG3 mRNA levels were express at very low only in undifferentiated hMSCs, whereas TG5 mRNA was undetectable in undifferentiated and differentiated hMSCs. Immunocytochemical and Western blot analysis showed an overexpression of TG2 in undifferentiated hMSCs. A dramatic reduction of the protein levels in 2 DIV GFs-treated cells was observed. Its expression levels progressively increased during the differentiation of hMSCs with GFs, reaching after 6 DIV of the treatment similar values to those observed in undifferentiated cells. Our findings demonstrate the presence of multiple TGs in hMSCs during neural differentiation in vitro induced by GFs, and suggest that TG2 may be part of the downstream events associated to neural differentiation.
Keywords: Growth factors, human mesenchymal stem cells, neural differentiation, neural markers, tissue transglutaminase, transglutaminases.
CNS & Neurological Disorders - Drug Targets
Title:Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells
Volume: 14 Issue: 1
Author(s): Luca Vanella, Giuseppina Raciti, Ignazio Barbagallo, Roberta Bonfanti, Nader Abraham and Agata Campisi
Affiliation:
Keywords: Growth factors, human mesenchymal stem cells, neural differentiation, neural markers, tissue transglutaminase, transglutaminases.
Abstract: Herein, we assessed the expression of transglutaminase-2 (TG2) during in vitro neural differentiation of human Mesenchymal Stem Cells (hMSCs) induced by some Growth Factors (GFs). The amount and distribution of mRNAs for some transglutaminase (TGs) isoforms (TG1, TG2, TG3, TG5) were also evaluated. In addition, we tested some neural lineage markers (Glial Acid Fibrillary Protein, GFAP; Neurofilament Protein, NF; Nestin; β-Tubulin III). A progressive increase of all neural markers during GFs neural differentiation of hMSCs was found. A significant overexpression of TG1 and TG2 mRNA was observed in undifferentiated hMSCs. GFs-treatment induced a progressive decrease of TG1 mRNA during hMSCs differentiation. A significant down-regulation of TG2 mRNA in 2 days in vitro (DIV) GFs-treated cells was observed. TG2 mRNA progressively increased during GFs hMSCs differentiation, reaching after 6 DIV of GFs-treatment of similar values to those observed in undifferentiated cells. TG3 mRNA levels were express at very low only in undifferentiated hMSCs, whereas TG5 mRNA was undetectable in undifferentiated and differentiated hMSCs. Immunocytochemical and Western blot analysis showed an overexpression of TG2 in undifferentiated hMSCs. A dramatic reduction of the protein levels in 2 DIV GFs-treated cells was observed. Its expression levels progressively increased during the differentiation of hMSCs with GFs, reaching after 6 DIV of the treatment similar values to those observed in undifferentiated cells. Our findings demonstrate the presence of multiple TGs in hMSCs during neural differentiation in vitro induced by GFs, and suggest that TG2 may be part of the downstream events associated to neural differentiation.
Export Options
About this article
Cite this article as:
Vanella Luca, Raciti Giuseppina, Barbagallo Ignazio, Bonfanti Roberta, Abraham Nader and Campisi Agata, Tissue Transglutaminase Expression During Neural Differentiation of Human Mesenchymal Stem Cells, CNS & Neurological Disorders - Drug Targets 2015; 14 (1) . https://dx.doi.org/10.2174/1871527314666150116111339
DOI https://dx.doi.org/10.2174/1871527314666150116111339 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prediction and Analysis of Hepatocellular Carcinoma Related Genes Using Gene Ontology and KEGG
Current Bioinformatics Neuronal Acetylcholine Nicotinic Receptors as New Targets for Lung Cancer Treatment
Current Pharmaceutical Design Cancer Stem Cells with Overexpression of Neuronal Markers Enhance Chemoresistance and Invasion in Retinoblastoma
Current Cancer Drug Targets Elucidation of the Molecular Mechanisms of a Salicylhydrazide Class of Compounds by Proteomic Analysis
Current Cancer Drug Targets Non-Photoinduced Biological Properties of Verteporfin
Current Medicinal Chemistry MicroRNAs in Lung Cancer and Lung Cancer Bone Metastases: Biomarkers for Early Diagnosis and Targets for Treatment
Recent Patents on Anti-Cancer Drug Discovery Silimarin and Cancer
Anti-Cancer Agents in Medicinal Chemistry Novel Marine-Derived Anti-Cancer Agents
Current Pharmaceutical Design Luminescent Silica Nanoparticles for Cancer Diagnosis
Current Medicinal Chemistry CDK5 and MAPT Gene Expression in Alzheimer's Disease Brain Samples
Current Alzheimer Research Targeting of NF-kappaB Signaling Pathway, other Signaling Pathways and Epigenetics in Therapy of Multiple Myeloma
Cardiovascular & Hematological Disorders-Drug Targets Stem Cell Pharmacogenomics
Current Topics in Medicinal Chemistry The Rb Pathway and Cancer Therapeutics
Current Drug Targets Antitumor Effects of Celastrol and Semi-Synthetic Derivatives
Mini-Reviews in Organic Chemistry Ribonucleases and ImmunoRNases as Anticancer Drugs
Current Pharmaceutical Design Structure and Functional Relationships of Hsp90
Current Cancer Drug Targets Vitamin D - Pivotal Nutraceutical in the Regulation of Cancer Metastasis and Angiogenesis
Current Medicinal Chemistry Recent Progress in Research on Ribosome Inactivating Proteins
Current Protein & Peptide Science Viral Based Gene Therapy for Prostate Cancer
Current Gene Therapy Anticancer Advances of Matrine and Its Derivatives
Current Pharmaceutical Design